Suppr超能文献

嗜铬细胞瘤患者围手术期发病率和死亡率的相关因素:单中心165例手术分析

Factors associated with perioperative morbidity and mortality in patients with pheochromocytoma: analysis of 165 operations at a single center.

作者信息

Plouin P F, Duclos J M, Soppelsa F, Boublil G, Chatellier G

机构信息

Department of Hypertension, Hôpital Broussais-Saint Joseph, 75908 Paris Cedex 15, France.

出版信息

J Clin Endocrinol Metab. 2001 Apr;86(4):1480-6. doi: 10.1210/jcem.86.4.7392.

Abstract

To identify preoperative factors associated with 30-day morbidity and mortality after pheochromocytoma surgery, we carried out an external review of the records of all patients undergoing pheochromocytoma surgery from 1975 to 1997 at a single center. One hundred and forty-seven patients, including 23 with malignant tumors at the time of the first operation, underwent 165 operations. Death, resection of a neighboring organ, further surgery, secondary transfer to an intensive care unit, and any events associated with a surgical stay exceeding 10 days were defined as complications. Mortality and morbidity were 4 of 165 (2.4%) and 38 of 161 (23.6%), respectively. Morbidity included 13 spleen resections and hematomas. Spleen complications were not related to tumor location, but were probably due to the operative strategy used, a transperitoneal complete abdominal exploration including both adrenal glands. Complications were independently associated with preoperative systolic blood pressure [odds ratio (OR), 1.14/cm Hg], urinary metanephrine excretion (OR, 1.18/10 micromol x day), and with the number of operations (repeat vs. first operation OR, 5.36). In conclusion, pheochromocytoma resection consistently involves a risk of complications. Spleen damage should be prevented by complete preoperative localization studies and an elective or laparoscopic surgical approach. Careful blood pressure control should help prevent complications. Patients with high secretion tumors and those undergoing repeat intervention are at high risk of complications and should be referred to centers familiar with pheochromocytoma management.

摘要

为了确定嗜铬细胞瘤手术后30天发病率和死亡率相关的术前因素,我们对1975年至1997年在单一中心接受嗜铬细胞瘤手术的所有患者的记录进行了外部回顾。147例患者接受了165次手术,其中包括23例初次手术时为恶性肿瘤的患者。死亡、邻近器官切除、再次手术、二次转入重症监护病房以及任何与手术住院时间超过10天相关的事件均被定义为并发症。死亡率和发病率分别为165例中的4例(2.4%)和161例中的38例(23.6%)。发病率包括13例脾切除和血肿。脾并发症与肿瘤位置无关,可能是由于所采用的手术策略,即包括双侧肾上腺的经腹完全腹部探查。并发症与术前收缩压[比值比(OR),1.14/厘米汞柱]、尿间甲肾上腺素排泄量(OR,1.18/10微摩尔/天)以及手术次数(再次手术与初次手术OR,5.36)独立相关。总之,嗜铬细胞瘤切除术始终存在并发症风险。应通过完善的术前定位研究和选择性或腹腔镜手术方法预防脾损伤。严格控制血压应有助于预防并发症。高分泌肿瘤患者和接受再次干预的患者并发症风险高,应转诊至熟悉嗜铬细胞瘤管理的中心。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验